23andMe

23andMe is a personal genomics and biotechnology company that provides direct-to-consumer genetic testing services. Its core offering includes ancestry composition reports that estimate an individual's genetic origins across global populations. The company also offers health-related reports that inform users about genetic predispositions to certain conditions and traits, subject to regulatory authorization. Customers collect a saliva sample at home and send it to the company's laboratory for genotyping using microarray technology. Results are delivered through a secure online portal where users can explore interactive tools and raw data downloads. The service is marketed primarily to individual consumers in the United States and is available in several other countries where regulations permit.

23andMe distinguishes itself by being one of the first companies to receive U.S. Food and Drug Administration authorization for certain direct-to-consumer health risk reports. The company operates a laboratory that meets federal clinical standards for genetic testing. In October 2023, the company disclosed a data breach that exposed personal information of a subset of its users, leading to multiple legal actions. Subsequent settlements in 2024 and 2025 resulted in compensation funds totaling tens of millions of dollars for affected claimants. Structurally, 23andMe is a publicly traded corporation listed on the NASDAQ stock exchange under the ticker symbol ME. Its headquarters are located in the United States.